CAR-T CELL THERAPY HUB · RESOURCE LIBRARY

Practice-Ready Resources for CAR-T Cell Therapy Implementation and Patient Care

Curated, practice-ready resources supporting the safe, effective implementation of CAR-T cell therapy — organized into Clinical Education, Agent-Specific Resources, and Example SOPs & Documents.

CAR-T Patient Journey

Referral

Apheresis

Manufacturing

Bridging Therapy

Lymphodepletion

Infusion & Monitoring

01 · FOUNDATIONS

Clinical Education

Build practical knowledge with focused education on CAR-T delivery, monitoring, and toxicity management.

Comparison of CAR-T Cell Therapies

Compare FDA-approved CAR-T therapies across indications, treatment requirements, efficacy, and key safety considerations.

View Resource →

CAR-T Toxicities Can Move Fast. Recognition Must Move Faster

Manage CAR-T toxicities with practical guidance on recognition, grading, treatment, escalation, and outpatient care.

View Resource →

Outpatient CAR-T: Same Powerful Therapy, Different Care Model

Explore outpatient CAR-T models, including patient selection, monitoring, escalation, and program readiness.

View Resource →

02 · UP CLOSE SERIES

Agent-Specific Resources

Get straight to the details with practical guidance for each FDA-approved CAR-T cell therapy.

Obecabtagene Autoleucel

AUCATZYL®

View AUCATZYL Resource →

Tisagenlecleucel

KYMRIAH®

View KYMRIAH Resource →

Axicabtagene Ciloleucel

YESCARTA®

View YESCARTA Resource →

Brexucabtagene Autoleucel

TECARTUS®

View TECARTUS Resource →

Lisocabtagene Maraleucel

BREYANZI®

View BREYANZI Resource →

Idecabtagene Vicleucel

ABECMA®

View ABECMA Resource →

Ciltacabtagene Autoleucel

CARVYKTI®

View CARVYKTI Resource →

03 · REAL-WORLD PRACTICE

Example SOPs & Documents

Explore example SOPs and practical implementation toolkits informed by best practices and real-world care.

SOP Document

CAR-T Center Coordination With a Community Cancer Center

This example standard operating procedure (SOP) provides a framework for CAR-T centers to coordinate care with community cancer centers throughout referral, patient evaluation, bridging therapy, lymphodepletion, infusion, acute toxicity management, transition of care, and long-term follow-up.

View Resource →

SOP Document

Community Practice Coordination With a CAR-T Treatment Center

This example standard operating procedure provides a framework for community oncology practices coordinating care with a CAR-T treatment center from early referral through long-term follow-up.

View Resource →

TOOLKIT

Community Cancer Center Working with CAR-T Centers

Practical guidance for coordinating CAR-T shared care across referral, bridging therapy, handoffs, urgent escalation, and long-term monitoring

View Resource →

TOOLKIT

Outpatient CAR-T Program Readiness Assessment and Implementation Roadmap

Structured readiness assessment and implementation roadmap for evaluating outpatient CAR-T program capability, identifying operational gaps, validating safety, and guiding a phased launch.

View Resource →

TOOLKIT

Outpatient CAR-T Toxicity and Rapid-Escalation Playbook

Role-based workflows for recognizing and responding to outpatient CAR-T toxicities, including triage, stabilization, treatment, transport, admission, and clinical handoff.

View Resource →

TOOLKIT

Outpatient CAR T Patient and Caregiver Eligibility, Education, and Monitoring Toolkit

Practical tools for outpatient CAR-T patient and caregiver eligibility, education, home monitoring, competency assessment, and rapid escalation of emerging toxicities.

View Resource →

• Gatwood K, Mahmoudjafari Z, Baer B, et al. Outpatient CAR T-cell therapy as standard of care: current perspectives and considerations. Clin Hematol Int. 2024;6(2):11-20. doi:10.46989/001c.115793

• Perez A, Al Sagheer T, Nahas GR, Linhares YPL. Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community-based centers. Front Immunol. 2024;15:1412002. doi:10.3389/fimmu.2024.1412002

• Oluwole OO, Dholaria B, Knight TE, et al. Chimeric antigen receptor T-cell therapy in the outpatient setting: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024;30(2):131-142. doi:10.1016/j.jtct.2023.11.008

• Furqan F, Bhatlapenumarthi V, Dhakal B, et al. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024;8(16):4320-4329. doi:10.1182/bloodadvances.2024013239

• Foundation for the Accreditation of Cellular Therapy. Standards for Immune Effector Cells in the Community Clinical Setting. 1st ed. Foundation for the Accreditation of Cellular Therapy; 2025.

• Foundation for the Accreditation of Cellular Therapy. Guidance to the Standards: First Edition FACT Immune Effector Cells in the Community Clinical Setting Accreditation Manual. Foundation for the Accreditation of Cellular Therapy; 2025.

• Perales MA, Dietrich J, Gust J, et al. ASTCT consensus grading for toxicities after immune effector cell therapy. Transplant Cell Ther. Published online September 8, 2026. doi:10.1016/j.jtct.2026.05.020

• Shahid Z, Jain T, Dioverti V, et al. Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies. Transplant Cell Ther. 2024;30(10):955-969. doi:10.1016/j.jtct.2024.07.018

• Roddie C, Neill L, Osborne W, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023;7(12):2872-2883. doi:10.1182/bloodadvances.2022009019

• Fandrei D, Seiffert S, Rade M, et al. Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma. Blood Cancer Discov. 2025;6(1):38-54. doi:10.1158/2643-3230.BCD-24-0118

CITATIONS

Recommended Reading

WITH GRATITUDE

Acknowledgements

Our heartfelt gratitude to all who contributed key insights to the development of these resources, including: